Xtraordinary Joy

Leylah Drusbosky, Ph.D., is a Medical Science Liaison at Guardant Health, a company that utilizes blood samples to guide personalized treatments in advanced cancer patients. She received her Ph.D. in molecular biology from the University of Florida and has expertise in next-generation sequencing, precision medicine, and translational research.

Kim Hawkins, Ph.D., is the Lead of Global Reagent Management for all vaccine R&D labs in Sanofi Pasteur. She received her Ph.D. in neuroscience at the University of Florida. She has experience investigating new treatment strategies for ischemic strokes, studying epigenetics of learning and memory, and neurogenetic viral therapy.

Coy Heldermon, MD, Ph.D., is an associate professor of medicine, board-certified medical oncologist with expertise in the treatment of breast cancer at the University of Florida. He is a member of the American Society of Hematology and the American Society of Clinical Oncology. His research expertise is in the use of gene replacement and stem cell therapies for the treatment of inherited disorders such as lysosomal storage diseases. He also studies the spread of stem cells from maternal or malignant sources using mouse models. Heldermon also serves as the faculty advisor for the Xtraordinary Joy Student Chapter at UF.

Naohiro Terada, MD, Ph.D., is professor of experimental pathology and director of the Center for Cellular Reprogramming at the University of Florida. He has published hundreds of research articles and served with numerous granting and publication agencies.

Generation of Induced Pluripotent Stem Cells from a Female Patient with a Xq27.3-q28 Deletion to Establish Disease Models and Identify Therapies

Xtraordinary Joy is proud to announce groundbreaking research publications.

Metabolomics and Lipidomics of Xq27.3-28 Neural Progenitors

Below are additional publications including further research regarding Xq27-q28 deletion.

Deletion Xq27.3q28 in female patient with global developmental delays and skewed X-inactivation

Microdeletions Including FMR1 in Three Female Patients with Intellectual Disability – Further Delineation of the Phenotype and Expression Studies

Clinical and molecular genetic characterization of two female patients harboring the Xq27.3q28 deletion with different ratios of X chromosome inactivation

Chromosomal Microarray Analysis (CMA) Detects a Large X Chromosome Deletion Including FMR1, FMR2, and IDS in a Female Patient With Mental Retardation